Last reviewed 2026-04-20 · How we verify

Orbactiv

At a glance

Approved indications

• Bacterial infection of skin
• Staphylococcal infection of skin
• Streptococcal infection of skin

Common side effects

• Headache
• Nausea
• Vomiting
• Limb and subcutaneous abscesses
• Diarrhea

Serious adverse events

• Cellulitis
• Osteomyelitis
• Hypersensitivity Reactions
• Infusion Related Reactions
• Clostridioides difficile-associated Diarrhea

Key clinical trials

• Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections (PHASE1)
• Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (PHASE2)
• Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
• Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
• Oritavancin for CIED Infections With MDR Gram-positive Cocci (NA)
• Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use (PHASE4)
• A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants (PHASE1)
• Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Orbactiv CI brief — competitive landscape report
• Orbactiv updates RSS · CI watch RSS
• Melinta Therapeutics, LLC portfolio CI